Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...

Related Keywords

United States ,San Diego ,California ,American ,Sikander Ailawadhi ,Francesco Passamonti ,Lisocabtagene Maraleucel ,Guillaume Cartron ,Ravi Vij ,Maroof Hasan ,Mark Kaplan ,Rachid Baz ,Hemophagocytic Lymphohistiocytosis ,Danny Jeyaraju ,Sheida Hayati ,Susan Bal ,Samit Hirawat ,Franck Morschhauser ,Bristol Myers Squibb ,Lauren Peres ,Sujit Sheth ,Marc Hoffmann ,Tracy Chow ,Hansc Lee ,Michael Wang ,Esther Oliva ,Leslie Andritsos ,Michele Delforge ,Ali Taher ,Manuel Ugidos Guerrero ,Loretta Nastoupil ,Ashley Saunders ,Alison Sehgal ,Michael Amatangelo ,Si Tuen Lee Hoeflich ,Srinivas Aluri ,Eniko Papp ,Hsiling Chiu ,Claire Harrison ,Valeria Santini ,Khaled Musallam ,Guillermo Garcia Manero ,Idecabtagene Vicleucel ,Kashyap Patel ,Tanya Siddiqi ,Kevin Kuo ,Paula Rodriguez Otero ,Maria Cappellini ,Paul Richardson ,Jennifer Crombie ,Julio Chavez ,Madhav Dhodapkar ,Doris Hansen ,November Mcgarvey ,Aiolos Ikaros ,Aaron Gerds ,Farrukh Awan ,Lara Stepan ,David Lavie ,Idecabtagene Vicleucel Ide ,Facebook ,Twitter ,Health Services ,Cel Versus Standard Regimens On Health ,Postinfusion Monitoring Health Care Resource Utilization ,Linkedin ,Marrow Transplant Research ,Acceleron Pharma Inc ,Outcomes Research ,American Society Of Hematology ,Health Outcomes ,International Blood ,Youtube ,Receptor Classc Group ,Instagram ,Global Drug Development ,Exchange Commission ,Flatiron Health ,Electronic Health Records ,American Society ,Annual Meeting ,Bristol Myers ,Underlying Disease Pathophysiology ,Ineffective Erythropoiesis ,Beta Thalassemia Receiving Luspatercept ,Biomarker Analysis ,Globin Gene Regulation ,World Characteristics ,Treatment Utilization ,Transfusion Burden ,Thalassemia Initiating Luspatercept ,Symptom Improvement ,Non Transfusion Dependent Thalassemia Treated ,Patient Reported Outcomes ,Patients Enrolled ,Long Term Rollover Study ,Final Safety ,Efficacy Data ,Subgroup Analysis ,Month Median Follow Up ,Lymphocytic Leukemia ,New Inhibitors ,Cellular Therapies ,Total Lifetime Cost ,Treating Patients ,Quality Improvement ,Lymphoid Malignancies ,Exploratory Analysis ,Lymphocytic Leukemias ,Real World Study ,Who Received Lisocabtagene Maraleucel ,Late Phase ,Commercially Available Therapies ,Cellular Therapy ,Prospective Clinical Trials ,Real World ,Second Line Therapy ,Patients Not Intended ,Hematopoietic Stem Cell Transplant ,Final Analysis ,Early Outcome Predictors ,Largeb Cell Lymphoma ,Translational Data ,Clinical Efficacy ,Previously Untreated Aggressiveb Cell Lymphoma ,Monitoring Health Care Resource Utilization ,Care Among Inpatients ,Refractory Largeb Cell Lymphoma ,Received Second Line Treatment ,Adjusted Indirect Comparison ,Third Line ,Follicular Lymphoma ,Reported Outcomes ,Seamless Design ,Primary Analysis Results ,Second Line High Risk Relapsed ,Refractory Follicular ,Refractory Indolentb Cell Non Hodgkin ,Subgroup Analyses ,High Risk Disease Features ,Release Syndrome ,Neurological Event Management Resource Use ,Costs Among Patients ,Efficacy Results ,Dose Expansion ,Prospective Therapeutic Trials ,Label Study ,Refractory Non Hodgkin Lymphoma ,Postinfusion Resource Use ,Total Costs ,Receiving Lisocabtagene Maraleucel ,Versus Standard Regimens ,Health Related Quality ,Refractory Multiple Myeloma ,Who Had Received ,Updated Results ,Coupled Receptor Classc Group ,Targeted Chimeric Antigen Receptor ,T Cell Therapy ,Early Phase ,Investigational Therapies ,Expanding Disease Targets ,Plasma Cell Dyscrasias ,Cell Maturation Antigen ,Cell Engager ,Administered Subcutaneously ,Human Clinical Study ,Inadequate Response ,Frontline Autologous Stem Cell Transplantation ,Extended Follow Up ,Receiving Idecabtagene Vicleucel ,Versus Standard ,Longitudinal Qualitative Interviews ,Translational Biomarker Analyses ,Inform Clinical Development ,Multiple Myeloma ,Resource Utilization ,Economic Burden ,Cytokine Release Syndrome ,Earlier Line Settings ,Real World Patients ,Triple Class Exposed ,Retrospective Study ,Who Received ,Prior Antimyeloma Regimens ,Predicting Outcome ,Side Effects ,Pro Inflammatory State ,Peak Cytokines Are Associated ,Early Responses ,Real World Multiple Myeloma Patients Treated ,Updated Analysis ,B Cell Acute Lymphoblastic Leukemia ,Clinical Trial ,Plus Dexamethasone ,Show Increased Genomic Aberrations Associated ,Significant Dysfunction ,T Cell Compartment Compared ,Patients With Triple Class ,Related Healthcare Resource Utilization ,Patients Treated ,Single Center Experience ,Luspatercept Versus Epoetin Alfa ,Erythropoiesis Stimulating Agent ,Naive Patients ,Lower Risk Myelodysplastic Syndromes ,Full Analysis ,Treatment Options ,Decision Making ,Low Risk ,Molecular Drivers ,Modulates Inflammation ,Bone Marrow ,Restores Effective ,Provides Sustained Clinical Benefit ,Epoetin Alfa ,Hematopoiesis Related Mutations Are Associated ,World Retrospective Study ,Non Transfusion Dependent Patients ,Myelodysplastic Syndromes ,Large Healthcare Claims Database ,Myeloid Malignancies ,Term Evaluation ,Refractory Patients ,Symptom Burden ,World Impact ,Prior Exposure ,Erythropoietin Stimulating Agents ,Large Healthcare Claims ,Low Risk Myelodysplastic Syndromes ,Genomic Landscape ,Mutational Burden ,Primary Endpoint Responses ,Treatment Patterns ,Real World Population ,Myelofibrosis Treated ,High Risk Myelofibrosis ,Allele Frequency ,Abnormal Cytokine Production ,Chronic Myeloid Leukemia ,Myelofibrosis Previously Treated ,Treatment Reduces ,Inflammatory Cytokine Profile ,Decreases Exhaustedt Cells Correlating ,Clinical Response ,Spleen Response ,Related Anemia Treated ,Efficacy Sub Analysis ,Risk Evaluation ,Mitigation Strategy ,Neurologic Toxicities ,Prescribing Information ,Macrophage Activation Syndrome ,Secondary Malignancies ,Operate Machinery ,North American ,Acceleron Pharma ,Lipase Elevation ,Adverse Cardiac Events ,Product Characteristics ,Profit Share Agreement ,Myers Squibb ,Better Future ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,